Deutsche Märkte geschlossen

Genetic Technologies Limited (GENE)

NasdaqCM - NasdaqCM Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
1,8200-0,0200 (-1,09%)
Börsenschluss: 04:00PM EDT
1,8199 -0,00 (-0,01%)
Nachbörse: 05:25PM EDT

Genetic Technologies Limited

60-66 Hanover Street
Fitzroy, VIC 3065
Australia
61 3 8412 7000
https://genetype.com

Sektor(en)Healthcare
BrancheDiagnostics & Research
Vollzeitmitarbeiter60

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Simon MorrissChief Executive Officer261,98kN/AN/A
Mr. Carl S. Stubbings BScChief Commercial Officer173,54kN/AN/A
Mr. Kevin CamilleriChief Executive Officer of EasyDNA167,48kN/AN/A
Ms. Kathryn J. E. Andrews B.Com., C.P.A., M.A.I.C.D.CFO & Company SecretaryN/AN/A1967
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIAConsultant119,26kN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Corporate Governance

Genetic Technologies Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.